Mercer Global Advisors
TEVA icon

Mercer Global Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Mercer Global Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.39M Sell
70,403
-5
-0% -$167 ﹤0.01% 1227
2026
Q1 		$2.12M Sell
70,408
-2,339
-3% -$75.3K ﹤0.01% 1171
2025
Q4 		$2.27M Buy
72,747
+3,874
+6% +$95.4K ﹤0.01% 1054
2025
Q3 		$1.39M Sell
68,873
-18,869
-22% -$331K ﹤0.01% 1203
2025
Q2 		$1.47M Buy
87,742
+9,120
+12% +$147K ﹤0.01% 1020
2025
Q1 		$1.21M Sell
78,622
-5,858
-7% -$105K ﹤0.01% 1043
2024
Q4 		$1.86M Sell
84,480
-7,756
-8% -$141K ﹤0.01% 853
2024
Q3 		$1.63M Sell
92,236
-5,403
-6% -$94.6K ﹤0.01% 832
2024
Q2 		$1.59M Sell
97,639
-252
-0.3% -$3.88K ﹤0.01% 785
2024
Q1 		$1.38M Buy
97,891
+26,293
+37% +$331K ﹤0.01% 833
2023
Q4 		$747K Sell
71,598
-48
-0.1% -$448 ﹤0.01% 1104
2023
Q3 		$731K Sell
71,646
-146
-0.2% -$1.36K ﹤0.01% 1074
2023
Q2 		$541K Sell
71,792
-111,165
-61% -$901K ﹤0.01% 1189
2023
Q1 		$1.62M Buy
182,957
+1,622
+0.9% +$16K 0.01% 744
2022
Q4 		$1.65M Sell
181,335
-90,696
-33% -$791K 0.01% 732
2022
Q3 		$2.19M Buy
272,031
+181,369
+200% +$1.6M 0.01% 606
2022
Q2 		$682K Buy
90,662
+54,692
+152% +$476K ﹤0.01% 999
2022
Q1 		$338K Sell
35,970
-4,554
-11% -$38K ﹤0.01% 1450
2021
Q4 		$325K Buy
40,524
+4,578
+13% +$41.3K ﹤0.01% 1426
2021
Q3 		$350K Sell
35,946
-8,861
-20% -$83K ﹤0.01% 1354
2021
Q2 		$444K Buy
44,807
+3,310
+8% +$35K ﹤0.01% 1202
2021
Q1 		$479K Sell
41,497
-37,577
-48% -$431K ﹤0.01% 1100
2020
Q4 		$763K Buy
79,074
+556
+0.7% +$5.33K 0.01% 708
2020
Q3 		$707K Buy
78,518
+56,839
+262% +$601K 0.01% 664
2020
Q2 		$267K Buy
21,679
+2,139
+11% +$24.2K ﹤0.01% 889
2020
Q1 		$175K Buy
+19,540
New +$200K ﹤0.01% 960

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Mercer Global Advisors's TEVA Position: Q2 2026 in Review

Mercer Global Advisors reduced its Teva Pharmaceuticals (TEVA) stake by 0.01% in Q2 2026, selling an estimated $167 and leaving 70,403 shares worth $2.39M. The position accounts for ﹤0.01% of the portfolio, ranked #1227.

Mercer Global Advisors first reported a position in TEVA in Q1 2020 and has held it in 26 quarters since. 673 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Mercer Global Advisors held 70,403 shares of Teva Pharmaceuticals worth $2.39M as of Q2 2026.
  • Mercer Global Advisors sold 5 Teva Pharmaceuticals shares in Q2 2026, an estimated $167.
  • Teva Pharmaceuticals made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #1227 holding.
  • Mercer Global Advisors first reported a position in Teva Pharmaceuticals in Q1 2020 and has held it in 26 quarters since.
  • 673 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.